Blood and tumor testing to choose the right lung cancer treatment
Part of Cancer, Lungs & breathing clinical trials.
This trial tests tumor tissue and a blood sample to help doctors pick the most personalized treatment for people with suspected lung cancer. It may help ensure you get therapy matched to your specific tumor characteristics, especially when the cancer might be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have suspected lung cancer that could be stage IA2 through stage III
- Doctors think the cancer might be operable (you could undergo treatment and possibly surgery if confirmed)
- If the diagnosis is confirmed by pathology (microscope testing), the cancer should be potentially resectable (removable)
- You do not have another active cancer at the same time (no concurrent malignancy)
- You have not had lung cancer in the past 2 years
- Your imaging finding is not only a “pure ground-glass” shadow (it must not be purely that type)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This trial is testing whether new blood tests can reliably detect and monitor stage III non-small cell lung cancer (NSCLC). It hopes to improve how doctors track your cancer and decide on treatment.
This trial checks whether a blood test that looks for cancer DNA can help guide and monitor treatment in people with advanced non-small cell lung cancer (NSCLC). It may help your team spot treatment response or changes earlier, so care can be adjusted appropriately.
This trial studies a “cell-free DNA” blood test to help diagnose and guide treatment decisions for early non-small cell lung cancer. It may help doctors tailor care based on genetic signals seen in the blood before and around surgery.
This study checks whether special blood testing plus computer-based review of tumor slides can help plan care for lung squamous cell cancer that can be removed by surgery. It looks at patients who have not had prior cancer treatment and who meet specific stage and health criteria.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.